Compare Ginkgo Bioworks Holdings Inc (DNA) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs United Microelectronics Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while United Microelectronics Corp trades at $22.96 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 76× Ginkgo Bioworks Holdings Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and United Microelectronics Corp for 42 Days on average.
| DNA | UMC | |
|---|---|---|
Market Cap | $763.64M | $58.02B |
Volume | 3,204,177 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $15.83 | $28.02 |
52-Week Low | $5.48 | $7.02 |
Typical Hold Time | 7 Days | 42 Days |
Enterprise Value | $865.59M | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
UMC trades at $22.82, down 2.1% over the past day, with a bullish technical signal but bearish moving averages. The company reported strong recent earnings beats, with Q2 2026 EPS of $0.54 versus $0.16 expected. Revenue for 2025 was $237.55B, with a net income margin of 16.99%. Analyst consensus is mixed, with 26.67% buy ratings and 53.33% hold. Recent news highlights AI-driven growth opportunities and a DCF intrinsic value estimate of $29.
The outlook for UMC is cautiously optimistic, driven by strong earnings performance and expanding AI opportunities. Key risks include competitive pressures in the semiconductor foundry space and potential volatility from AI spending fluctuations. The stock's current valuation metrics, including a P/E of 22.03, suggest room for growth if earnings trends continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
